← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV17행 · 1개 프로그램
OverviewPK/PDToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyLimited DatastalePhase 1
Vanucizumab (Vanucizumab)
Hoffmann-La Roche·Neoplasms
3 trials·t½ 9 h
Overview
Program
Vanucizumab
Overview
Company
Hoffmann-La Roche
Overview
Modality
ANTIBODY
Overview
Target
Neoplasms
Overview
Indication
Neoplasms
Overview
Phase
PHASE_1
Overview
Status
ACTIVE
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
PK/PD
Half-life
9 h
Toxicology
Major finding
Angiopoietin inhibitors: A review on targeting tumor angiogenesis.. Angiogenesis is the process of formation of new blood vessels from existing ones. Vessels serve the purpose of providing oxygen, nutrients and removal of waste from the cells. The physiological angiogenesis is a normal process and is required in the embryonic development, wound healing, menstrual cycle. For homeostasis, balance of…
Clinical
Safety signal
Angiopoietin inhibitors: A review on targeting tumor angiogenesis.. Angiogenesis is the process of formation of new blood vessels from existing ones. Vessels serve the purpose of providing oxygen, nutrients and removal of waste from the cells. The physiological angiogenesis is a normal process and is required in the embryonic development, wound healing, menstrual cycle. For homeostasis, balance of…
Clinical
Result source
ClinicalTrials.gov NCT02141295
Clinical
Program phase
PHASE_1
Clinical
Trial ref
NCT02141295